Matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), play critical roles in maintaining the extracellular matrix (ECM) and regulating physiological processes such as tissue remodeling, angiogenesis, and cell proliferation. MMPs are a family of zinc-dependent proteases that degrade ECM components, while TIMPs inhibit MMP activity and regulate ECM turnover. Imbalances between MMPs and TIMPs are associated with various diseases, including diabetes, neurodegenerative disorders, and cancer. In diabetes, altered MMP and TIMP expression contributes to vascular complications, kidney damage, and neuropathy. In neurodegenerative diseases like multiple sclerosis (MS) and Parkinson’s disease (PD), MMPs and TIMPs are involved in BBB disruption, neuroinflammation, and neuronal damage. In MS, elevated MMP-9 and reduced TIMP-1 levels are linked to disease progression, while in PD, MMP overexpression and TIMP regulation influence neuronal death. In wound healing, MMPs and TIMPs balance ECM remodeling and tissue repair, but dysregulation leads to poor healing in diabetic patients. In renal diseases, MMPs and TIMPs regulate ECM degradation and fibrosis, with altered expression contributing to kidney injury. Overall, understanding the regulation of MMPs and TIMPs is crucial for developing therapeutic strategies targeting these enzymes in disease management.Matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), play critical roles in maintaining the extracellular matrix (ECM) and regulating physiological processes such as tissue remodeling, angiogenesis, and cell proliferation. MMPs are a family of zinc-dependent proteases that degrade ECM components, while TIMPs inhibit MMP activity and regulate ECM turnover. Imbalances between MMPs and TIMPs are associated with various diseases, including diabetes, neurodegenerative disorders, and cancer. In diabetes, altered MMP and TIMP expression contributes to vascular complications, kidney damage, and neuropathy. In neurodegenerative diseases like multiple sclerosis (MS) and Parkinson’s disease (PD), MMPs and TIMPs are involved in BBB disruption, neuroinflammation, and neuronal damage. In MS, elevated MMP-9 and reduced TIMP-1 levels are linked to disease progression, while in PD, MMP overexpression and TIMP regulation influence neuronal death. In wound healing, MMPs and TIMPs balance ECM remodeling and tissue repair, but dysregulation leads to poor healing in diabetic patients. In renal diseases, MMPs and TIMPs regulate ECM degradation and fibrosis, with altered expression contributing to kidney injury. Overall, understanding the regulation of MMPs and TIMPs is crucial for developing therapeutic strategies targeting these enzymes in disease management.